Danish pharmaceutical company Novo Nordisk (NYSE: NVO) is pioneering a new wave of medical treatment for diabetes and obesity ...

Critics, including Senator Bernie Sanders, question whether the push to block alternatives is truly about safety — or simply ...

Novo Nordisk is urging the U.S. Food and Drug Administration (FDA) to block ‘copycat’ versions of its popular weight-loss and ...

The full-year cost of care for U.S. patients with obesity, two years after starting on Novo Nordisk's Wegovy or similar GLP-1 ...

A new class of weight-loss drugs is changing the food industry, but not in the way many expected at first. They could present ...

The University of California, Davis today announced an expanded collaboration with the BioInnovation Institute (BII) to ...

The active ingredient in Ozempic and Wegovy has once again proven to have health effects outside of weight loss in a huge ...

In Quebec, anti-obesity medications are on the list of exclusions of the Régie de l’assurance maladie du Québec (RAMQ). Quebec is the only Canadian province that does not evaluate obesity medications ...

City employees in NYC had insurance coverage for GLP-1 drugs like Wegovy and Zepbound for less than a year before learning it ...

Chip giant Nvidia has developed a supercomputer for Danish pharma company Novo Nordisk, the maker of blockbuster weight loss ...

Benzinga examined the prospects for many investors’ favorite stocks over the last week — here’s a look at some of our top ...

It has been estimated that 90% of medical device waste consists of single-use products or components, so a new initiative by Novo Nordisk to recycle pre-filled injection pens used by people living ...